| Non-small-cell lung cancer C Gridelli, A Rossi, DP Carbone, J Guarize, N Karachaliou, T Mok, ... Nature reviews Disease primers 1 (1), 1-16, 2015 | 899 | 2015 |
| The Hippo effector YAP promotes resistance to RAF-and MEK-targeted cancer therapies L Lin, AJ Sabnis, E Chan, V Olivas, L Cade, E Pazarentzos, S Asthana, ... Nature genetics 47 (3), 250-256, 2015 | 533 | 2015 |
| Genetics and biomarkers in personalisation of lung cancer treatment R Rosell, TG Bivona, N Karachaliou The Lancet 382 (9893), 720-731, 2013 | 358 | 2013 |
| Targeting RET in patients with RET-rearranged lung cancers: results from the global, multicenter RET registry O Gautschi, J Milia, T Filleron, J Wolf, DP Carbone, D Owen, R Camidge, ... Journal of Clinical Oncology 35 (13), 1403, 2017 | 350 | 2017 |
| RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer G Hrustanovic, V Olivas, E Pazarentzos, A Tulpule, S Asthana, ... Nature medicine 21 (9), 1038-1047, 2015 | 295 | 2015 |
| The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in … C Costa, MA Molina, A Drozdowskyj, A Giménez-Capitán, ... Clinical cancer research 20 (7), 2001-2010, 2014 | 278 | 2014 |
| KRAS mutations in lung cancer N Karachaliou, C Mayo, C Costa, I Magrí, A Gimenez-Capitan, ... Clinical lung cancer 14 (3), 205-214, 2013 | 273 | 2013 |
| Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial N Karachaliou, C Mayo-de las Casas, C Queralt, I de Aguirre, B Melloni, ... JAMA oncology 1 (2), 149-157, 2015 | 266 | 2015 |
| Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification B Bulik-Sullivan, J Busby, CD Palmer, MJ Davis, T Murphy, A Clark, ... Nature biotechnology 37 (1), 55-63, 2019 | 264 | 2019 |
| Swarm intelligence-enhanced detection of non-small-cell lung cancer using tumor-educated platelets MG Best, N Sol, S GJG, A Vancura, M Muller, ALN Niemeijer, AV Fejes, ... Cancer cell 32 (2), 238-252. e9, 2017 | 263 | 2017 |
| Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients N Karachaliou, M Gonzalez-Cao, G Crespo, A Drozdowskyj, E Aldeguer, ... Therapeutic advances in medical oncology 10, 1758834017749748, 2018 | 254 | 2018 |
| Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial R Rosell, U Dafni, E Felip, A Curioni-Fontecedro, O Gautschi, S Peters, ... The Lancet Respiratory Medicine 5 (5), 435-444, 2017 | 214 | 2017 |
| Small cell lung cancer: can recent advances in biology and molecular biology be translated into improved outcomes? PA Bunn Jr, JD Minna, A Augustyn, AF Gazdar, Y Ouadah, MA Krasnow, ... Journal of Thoracic Oncology 11 (4), 453-474, 2016 | 203 | 2016 |
| Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer RJA Nilsson, N Karachaliou, J Berenguer, A Gimenez-Capitan, ... Oncotarget 7 (1), 1066, 2016 | 203 | 2016 |
| Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis M Duruisseaux, A Martínez-Cardús, ME Calleja-Cervantes, S Moran, ... The Lancet Respiratory Medicine 6 (10), 771-781, 2018 | 189 | 2018 |
| Human endogenous retroviruses and cancer M Gonzalez-Cao, P Iduma, N Karachaliou, M Santarpia, J Blanco, ... Cancer biology & medicine 13 (4), 483, 2016 | 180 | 2016 |
| Real-time liquid biopsies become a reality in cancer treatment N Karachaliou, C Mayo-de-Las-Casas, MA Molina-Vila, R Rosell Annals of translational medicine 3 (3), 2015 | 178 | 2015 |
| Co-activation of STAT3 and YES-associated protein 1 (YAP1) pathway in EGFR-mutant NSCLC I Chaib, N Karachaliou, S Pilotto, J Codony Servat, X Cai, X Li, ... JNCI: Journal of the National Cancer Institute 109 (9), djx014, 2017 | 154 | 2017 |
| Large-scale screening for somatic mutations in lung cancer R Rosell, N Karachaliou The Lancet 387 (10026), 1354-1356, 2016 | 140 | 2016 |
| Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer K Jacobsen, J Bertran-Alamillo, MA Molina, C Teixidó, N Karachaliou, ... Nature communications 8 (1), 410, 2017 | 138 | 2017 |
